The estimated Net Worth of Capital Ii Ventech is at least 2.2 百万$ dollars as of 13 March 2017. Capital Ventech owns over 4,419 units of Scynexis Inc stock worth over 2,004,540$ and over the last 11 years Capital sold SCYX stock worth over 194,867$.
Sign up
Capital Ventech SCYX stock SEC Form 4 insiders trading
Capital has made over 5 trades of the Scynexis Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Capital sold 4,419 units of SCYX stock worth 12,373$ on 13 March 2017.
The largest trade Capital's ever made was buying 102,777 units of Scynexis Inc stock on 19 February 2015 worth over 616,662$. On average, Capital trades about 38,639 units every 208 days since 2014. As of 13 March 2017 Capital still owns at least 1,431,814 units of Scynexis Inc stock.
You can see the complete history of Capital Ventech stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Capital Ventech's mailing address?
Capital's mailing address filed with the SEC is 47 AVENUE DE L'OPERA, , PARIS, I0, 75002.
Insiders trading at Scynexis Inc
Over the last 10 years, insiders at Scynexis Inc have traded over 4,708,140$ worth of Scynexis Inc stock and bought 2,173,590 units worth 13,469,713$ . The most active insiders traders include Advisors Llcperceptive Life...、Patrick Machado、Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of 64,694$. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth 225,000$.
What does Scynexis Inc do?
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
What does Scynexis Inc's logo look like?
Complete history of Capital Ventech stock trades at AB Active ETFs Inc、Scynexis Inc
Scynexis Inc executives and stock owners
Scynexis Inc executives and other stock owners filed with the SEC include:
-
Dr. Marco Taglietti M.D.,
CEO, Pres & Director -
Dr. Marco Taglietti,
CEO, Pres & Director -
David Gonzalez Angulo,
Chief Medical Officer -
Eric Francois,
Chief Financial Officer -
Christine R. Coyne M.B.A.,
Chief Commercial Officer -
Philippe Tinmouth,
Director -
Jean-Yves Nothias,
Director -
Guy Macdonald,
Director -
Patrick Langlois,
Director -
David Hastings,
Director -
Ann Hanham,
Director -
Steven Gilman,
Director -
Laurent Arthaud,
Director -
Armando Anido,
Director -
David Angulo,
Chief Medical Officer -
Scott Sukenick,
General Counsel -
Nkechi Azie,
Vice President - Clinical Development -
Jim Maffezzoli,
Vice President of Sales and Marketing -
Eric Francois,
Chief Financial Officer -
Marco Taglietti,
President, Chief Executive Officer, Director -
Pamela Kirby,
Chairman of the Board -
Debbie Etchison,
Exec. Director of Communications -
Lawrence R. Hoffman CPA, Esq.,
Interim CFO & Principal Accounting Officer -
Dr. Rajeshwar Motheram,
Sr. VP of Pharmaceutical Devel. & Supply Chain -
Scott Sukenick J.D.,
Gen. Counsel & Corp. Sec. -
Patrick Machado,
Director -
Marion Mc Court,
Director -
Jr. Charles F Osborne,,
Chief Financial Officer -
Biopharma Partners Ii Lpalt...,
-
Carole Sable,
Chief Medical Officer -
Capital Ii Ventech,
10% owner -
Biotechnology Fund Fcpr,
10% owner -
Eileen Pruette,
General Counsel -
Genavent F.C.P.R.,
10% owner -
Mounia Chaoui,
Director -
Edward Penhoet,
Director -
Yves J Ribeill,
President and CEO -
Advisors Llcperceptive Life...,
-
Christine Coyne,
Chief Commercial Officer -
Ivor Macleod,
Chief Financial Officer